Letter to the EditorChemotherapy directly followed by poly(ADP-ribose) polymerase inhibition as an alternative to surgery in patients with BRCA-mutated ovarian cancer: a potential management strategy in the era of coronavirus disease 2019
Cited by (0)
L.J.C. was on an Ad Board for AstraZeneca in 2018. The other authors report no conflict of interest.
This communication has been published in the middle of the COVID-19 pandemic and is available via expedited publication to assist patients and healthcare providers.
© 2020 Elsevier Inc. All rights reserved.